Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease
Sex Difference of Coronary Microvascular Dysfunction Evaluated by Coronary Flow Reserve in Patients With Non-obstructive Coronary Artery Disease
Korea University Anam Hospital
300 participants
Feb 1, 2018
OBSERVATIONAL
Conditions
Summary
Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease
Eligibility
Inclusion Criteria2
- Typical/atypical chest pain or ischemic symptoms including dyspnea
- No significant coronary artery stenosis (\<50% stenosis) in coronary angiography or computed tomography
Exclusion Criteria7
- ≥ Moderate valvular heart disease
- Congenital heart disease
- Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis
- Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension
- Receiving anticancer drugs
- Vasculitis associated with autoimmune diseases
- Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood flow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel flow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary flow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06076551